Optimization of Exenatide plus Detemir Treatment for Morbid Obese Patients with Insulin Dependent Diabetes Resistant to Conventional Treatment. Effect of Exenatide on Patients with Mellitus Diabetes Type 2

Autor:	Alfonso López Ruiz, María Ángeles Núñez Sánchez, Noelia Victoria García-Talavera Espín, Amparo Meoro Avilés, Cristina del Peso Gilsanz, Ricardo Soriano Sánchez, María Teresa Gallego García, José Soriano Palao, María Dolores Ortuño, Sacramento Tomás Navarro, Collaborative Groups of the Diabetes and Obesity Unit of the Hospital Reina Sofía
Rok vydání:	2014
Předmět:	medicine.medical_specialty Longitudinal study business.industry Insulin medicine.medical_treatment Type 2 Diabetes Mellitus medicine.disease Gastroenterology Blood pressure Endocrinology Internal medicine Diabetes mellitus medicine business Exenatide Body mass index medicine.drug Insulin detemir
Zdroj:	Pharmacology & Pharmacy. :433-443
ISSN:	2157-9431 2157-9423
DOI:	10.4236/pp.2014.54053
Popis:	The purpose of this study was to analyze the effects of the treatment with Exenatide joint to insulin detemir. The study was carried out with obese patients with type 2 diabetes mellitus (DM2) and deficient control, despite intensive insulin therapy combined with oral antidiabetics. A longitudinal study was made with 15 patients controlled by the Endocrinology and Nutrition Section of the Reina Sofia University Hospital, Murcia. These patients were treated with Exenatide joint to insulin during 3, 6 and 12 months. Statistically meaningful differences (p＜0.05) were observed in the reduction of HbA1c in the 3 and 6 months treatment groups (initial HbA1c: 9.55%±1.086%, weight: 119.94kg, insulin requirement: 0.71 IU/kg/day; after 3 months: HbA1c: 7.77%±1.164%, weight: 98.13kg, insulin requirement: 0.59 IU/kg/day; after 6 months: HbA1c: 7.21%, weight: 97.93kg, insulin requirement: 0.55 IU/kg/day). It was observed that the association of Exenatide and insulin promotes an improvement in several indicators such as weight, body mass index (BMI), systolic pressure (SP), diastolic pressure (DP), triglycerides (TG), cLDL, cHDL and total cholesterol (TC), in patients with diabetes resistant to conventional therapy. However, these improvements were statistically no significant (p＜0.05). It is possible to talk of a reduction of cardiovascular risk factors in patients with Exenatide, being thus a suitable option for this kind of individuals. It is important to emphasize the fact that our study showed bigger body-weight reductions results after 6 and 12 months, as compared to the researches quoted.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::68f8a7559ebf273838a0b0807719690d https://doi.org/10.4236/pp.2014.54053 Zobrazit plný text záznamu